Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study
- 4 August 2020
- journal article
- research article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (11) , 1050-1059
Abstract
Objective We identified factors influencing outcomes in patients with medically inoperable early‐stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey. Methods We retrospectively analyzed 431 patients with stage I‐II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction, and biologically effective dose with an α/β ratio of 10 (BED10); tumor location; and treatment center were evaluated for associations with overall survival (OS), local control (LC), and toxicity. Results Median follow‐up time was 27 months (range 1–115); median SABR dose was 54Gy (range 30–70) given in a median 3 fractions (range 1–10); median BED10 was151 Gy (range 48–180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%), and 100Gy (p =0.011), adenocarcinoma (p =0.025), and complete response on first evaluation (p =0.007) predicted favorable LC. BED10>120Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1–3.2,p =0.019) and tumor size (p =0.003) predicted favorable OS. No grade 4‐5 acute side effects were observed; late effects were grade ≤3 pneumonitis (18 [4.2%]), chest wall pain (11 [2.5%]), and rib fracture (1 [0.2%]). Conclusion SABR produced encouraging results, with satisfactory LC and OS and minimal toxicity. BED10>120 Gy was needed for better LC and OS for large, non‐adenocarcinoma tumors.Keywords
This publication has 31 references indexed in Scilit:
- Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 TrialJournal of Clinical Oncology, 2019
- Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 MonthsJournal of Thoracic Oncology, 2016
- Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial treePractical Radiation Oncology, 2016
- Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR CohortClinical Oncology, 2016
- Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Stereotactic Body Radiation Therapy in Multiple Organ SitesJournal of Clinical Oncology, 2007
- Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung CancerJournal of Clinical Oncology, 2006
- Extracranial Stereotactic Radioablation *Chest, 2003
- Local irradiation alone for peripheral Stage I lung cancer: Could we omit the elective regional nodal irradiation?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996